Edition:
United States

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

17.23USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$17.23
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
27,140
52-wk High
$23.36
52-wk Low
$2.77

Chart for

About

GTx, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecules for the treatment of cancer, including treatments for breast and prostate cancer, and other medical conditions. The Company is engaged in the development of selective androgen receptor modulators (SARMs). Its... (more)

Overall

Beta: 1.60
Market Cap(Mil.): $380.06
Shares Outstanding(Mil.): 21.86
Dividend: --
Yield (%): --

Financials

  GTXI.OQ Industry Sector
P/E (TTM): -- 178.44 32.31
EPS (TTM): -1.75 -- --
ROI: -104.69 -0.73 12.97
ROE: -104.69 -2.77 14.84

BRIEF-GTX Announces Early Completion Of Patient Enrollment In The Astrid Trial

* GTX ANNOUNCES EARLY COMPLETION OF PATIENT ENROLLMENT IN THE ASTRID TRIAL, A PHASE 2 CLINICAL TRIAL OF ENOBOSARM IN STRESS URINARY INCONTINENCE

Apr 09 2018

BRIEF-GTX Inc Q4 Loss Per Share $0.43

* GTX PROVIDES CORPORATE UPDATE AND REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 12 2018

BRIEF-GTx Announced New Data Demonstrating Enobosarm's Potential To Treat Stress Urinary Incontinence At SUFU 2018

* GTX ANNOUNCED NEW DATA DEMONSTRATING ENOBOSARM’S POTENTIAL TO TREAT STRESS URINARY INCONTINENCE AT SUFU 2018

Mar 05 2018

BRIEF-GTx Trial Results In Stress Urinary Incontinence Accepted For Podium Presentation At SUFU

* GTX PHASE 2 ENOBOSARM CLINICAL TRIAL RESULTS IN STRESS URINARY INCONTINENCE ACCEPTED FOR PODIUM PRESENTATION AT SUFU Source text for Eikon: Further company coverage:

Feb 22 2018

BRIEF-GTX Inc Files For Mixed Shelf Offering Of Up To $150 Mln

* GTX INC FILES FOR MIXED SHELF OFFERING OF UP TO $150 MILLION - SEC FILING Source text: (http://bit.ly/2kHuojK) Further company coverage:

Dec 22 2017

BRIEF-GTX reports qtrly ‍loss per share $0.53​

* GTX provides corporate update and reports third quarter 2017 financial results

Nov 14 2017

Earnings vs. Estimates